Taro Pharmaceutical Industries Ltd. (TARO) NYSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1554
First IPO Date
September 14, 1982
| Name | Title | Pay | Year Born |
| Uday V. Baldota | Chief Executive Officer & Director | 0 | 1970 |
| Ara Aprahamian | Vice President of Sales & Marketing | 616,143 | 1968 |
| Roman Kaplan | Vice President of Scientific and Technical Compliance Manager | 0 | 1947 |
| Jayesh Shah | Head of Procurement | 0 | 1956 |
| Avi Avramoff | Vice President and Head of R&D | 0 | 1965 |
| Erik Zwicker | Vice President, General Counsel & Secretary | 0 | 1980 |
| Itamar Karsenti | Vice President & Head of Operations | 0 | 1972 |
| Itzik Baruch | Vice President of Technical Services | 0 | 1963 |
| William J. Coote | Vice President, Chief Financial Officer & Chief Accounting Officer | 0 | 1955 |
| Michele Visosky | Vice President & Head of Human Resource | 0 | 1966 |
Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven pharmaceutical enterprise, specializing in the development, manufacturing, and commercialization of both prescription and over-the-counter medications. Its market reach spans the United States, Canada, Israel, and various other international territories. The company also produces active pharmaceutical ingredients (APIs), primarily for integration into its own finished dosage form products. Its extensive product catalog addresses a broad spectrum of medical conditions and therapeutic areas, encompassing treatments for allergies, pain (analgesic), bacterial and fungal infections (antibacterial, antibiotic, antifungal), seizures (anticonvulsant), nausea (antiemetic), inflammation (anti-inflammatory), cancer (anti-cancer, topical anti-neoplastic), blood clot prevention (antiplatelet agent), fever reduction (antipyretic), cardiovascular issues, central nervous system disorders, hormonal regulation (corticosteroid, endocrine), cosmetic applications, coughs and colds, dermatological complaints, fluid management (diuretic), gastrointestinal problems, constipation (laxative), severe pain (narcotics), neuropathic pain, neuropsychiatric conditions, and sleep/anxiety management (sedative/hypnotic). These pharmaceutical goods are available in numerous formats, including capsules, creams, drops, emulsions, gels (and gel kits), granules, injectables, lotions, oils, ointments, pastes, powders (and powders for solution), rectal suppositories, shampoos, solutions (and solutions for infusion), sprays, suspensions, syrups, tablets, toothpastes and mouthwashes, topical foams, and topical solutions. Taro distributes and sells its products directly to a wide array of clients, such as pharmaceutical wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, other direct purchasers, and various healthcare institutions and private pharmacies. The company was established in 1950, with its main offices situated in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a wholly-owned subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.